Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin.
We have incorporated the IRT assay for CF to our newborn screening program, relying heavily on electronic data processing to optimize the test results in order to provide the most reliable data possible from the specimen at hand. We have established an internal cut-off of 100 ng/mL and an external referral of 180 ng/mL; this virtually eliminates the possibility that analytical imprecision will result in misidentifying a positive patient specimen. The relationship between IRT levels and various mutant forms of CF are not well established, and it is possible that various forms of CF may exhibit different levels of IRT in the first few days of life. We believe that IRT screening for CF could be a useful procedure for early identification of potential CF. However, by comparison with other newborn screening tests, its sensitivity, 90%, presents a concern. The expectation for PKU, hypothyroidism, MSUD, and galactosemia screening is 100% sensitivity. A false-negative usually results in litigation. The use of IRT in routine newborn screening will require considerable education of the general public and physicians receiving test results. Our program, along with many others, is anxiously watching the developments in the area of gene testing. We feel the relatively inexpensive IRT, used for mass screening can be successfully coupled with the more definitive (and expensive) gene test on a selected population to identify CF at the earliest possible age in a more effective manner. It is possible that in the near future gene probe tests will be applied in a cost effective manner to the initial filter paper specimen.
Hassemer
D J
DJ
State Laboratory of Hygiene, Madison, WI 53706.
Laessig
R H
RH
Hoffman
G L
GL
Farrell
P M
PM
D003550:Cystic Fibrosis / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D001330:Electronic Data Processing; D005069:Evaluation Studies as Topic; D006801:Humans; D007231:Infant, Newborn; D007753:Laboratories; D015997:Neonatal Screening / Q000592:standards*; D011237:Predictive Value of Tests; D011786:Quality Control; D014357:Trypsin / Q000097:blood*; D014922:Wisconsin / Q000453:epidemiology
D014357:Trypsin